Table 3.

Selected MTNR1a and MTNR1b SNPS and breast cancer risk, by stage and menopausal status, the Shanghai Breast Cancer Study

	cases	control	MAFa	OR-additive (AB)b	OR-additive (BB)b	p-trend	OR-recessiveb	P-recessive
MTNR1a rs7665392
Stage I	958	962	0.2443	0.77(0.64– 0.94)	0.80(0.54– 1.18)	0.0150	0.88(0.60– 1.29)	0.5074
Stage II	966	974	0.2079	1.15(0.95– 1.38)	1.47(0.93– 2.33)	0.0476	1.40(0.89– 2.20)	0.1514
Combined	1924	1936	0.2260	0.94(0.82– 1.08)	1.05(0.78– 1.41)	0.6593	1.07(0.80– 1.43)	0.6424
Premenopausal (combined)	1191	1141	0.2217	0.91(0.77– 1.08)	1.52(1.03– 2.24)	0.5720	1.57(1.07– 2.31)	0.0198
Premenopausal stage I	665	626	0.2188	0.78(0.62– 0.99)	1.18(0.73– 1.90)	0.3541	1.29(0.80– 2.06)	0.2954
Premenopausal stage II	526	515	0.2068	1.10(0.85– 1.42)	2.42(1.23– 4.76)	0.0446	2.33(1.20– 4.56)	0.0130
Postmenopausal (combined)	733	795	0.2321	1.00(0.81– 1.24)	0.58(0.35– 0.96)	0.1864	0.58(0.36– 0.95)	0.0303
Postmenopausal stage I	293	336	0.2634	0.76(0.55– 1.07)	0.33(0.15– 0.73)	0.0043	0.37(0.17– 0.80)	0.0113
Postmenopausal stage II	440	459	0.2092	1.21(0.92– 1.61)	0.87(0.45– 1.70)	0.4514	0.81(0.42– 1.57)	0.5402
MTNR1b rs10765576
Stage I	959	963	0.3063	0.94(0.78– 1.13)	0.78(0.57– 1.08)	0.1489	0.80(0.59– 1.10)	0.1672
Stage II	967	974	0.2834	1.16(0.96– 1.40)	0.79(0.56– 1.11)	0.9937	0.74(0.53– 1.03)	0.0757
Combined	1926	1937	0.2948	1.04(0.91– 1.19)	0.79(0.63– 0.99)	0.2823	0.78(0.62– 0.97)	0.0281
Premenopausal (combined)	1193	1141	0.2958	0.99(0.83– 1.17)	0.73(0.54– 0.98)	0.1203	0.73(0.55– 0.98)	0.0339
Postmenopausal (combined)	733	796	0.2933	1.13(0.91– 1.39)	0.90(0.62– 1.32)	0.7961	0.85(0.59– 1.23)	0.3903

^aMinor allele frequency among genotyped controls

^bModel of effect: additive: AB or BB versus AA, or recessive: BB versus AA and AB; AA major allele homozygotes, AB heterozygotes, BB minor allele homozygotes. Major/minor alleles as determined by allele frequency among genotyped controls. ORs adjusted for age, education, and study stage.